A team co-led by researchers at The Institute of Cancer Research, London, has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC ...

Being overweight or obese is an important cause of rising cancer rates among younger adults in England, according to a major new study. Researchers at The Institute of Cancer Research, London, and ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Do I need a UK visa? If you do not meet one of the following criteria, then it is likely you will need a visa to come to study in the UK or you will have restrictions on what you can do while studying ...

Over 80% of breast cancer (BC) patients in the developed western world have oestrogen receptor (ER)–positive disease. Standard treatment typically includes surgery and adjuvant endocrine therapy (ET), ...

With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow ...

These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...

A pioneering clinical trial has demonstrated for the first time that two existing treatments can be combined to potentially improve outcomes for sarcoma and melanoma patients with advanced tumours in ...

Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at ...

A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports. Almost half of the patients in the trial that could be evaluated saw their tumour shrink after ...

We share the story of a pioneering and collaborative research programme at the ICR, initiated in the late 1990s, that led to one of the first clinical-stage PI3K inhibitors, laying the foundation for ...